At 2.9% CAGR, the Europe Overactive Bladder Treatment Market is projected to be worth US$ 1,318.55 Million by 2028, says Business Market Insights

According to Business Market Insights’ research, the Europe overactive bladder treatment market was valued at US$ 1,111.05 million in 2022 and is expected to reach US$ 1,318.55 million by 2028, registering a CAGR of 2.9% from 2022 to 2028. Increase in prevalence of urinary incontinence and growing incidence of urinary tract infections are the critical factors attributed to the market Europe overactive bladder treatment expansion.  

Urinary incontinence is the loss of bladder control caused due to the improper functioning of the muscles and nerves that control the passage of urine through the bladder. Stress incontinence and urge incontinence are the two common types of urinary incontinence affecting women, wherein the latter is also known as overactive bladder. Other factors affecting the function of muscles and nerves include overweight, constipation, or pelvic surgeries. Although urinary incontinence may affect women at any age, it is more common in elderly women; this is mainly due to hormonal changes during menopause. According to the NHS, ~4 in every 10 women aged 65 and older have urinary incontinence. As per the HCA UK (a healthcare provider), ~3 million people in the UK are affected by urinary incontinence, of which 15% of women and ~5% of men are in their mid-40s. Thus, the growing prevalence of urinary incontinence favors the growth of the Europe overactive bladder treatment market.

On the contrary, recalls of therapeutic drugs hurdles the growth of Europe overactive bladder treatment market.

• Based on pharmacotherapy, the Europe overactive bladder treatment market is segmented into anticholinergics, mirabegron, botox, neurostimulation, and intravesical instillation. The mirabegron segment held 37.8% market share in 2022, amassing US$ 420.33 million. It is projected to garner US$ 506.64 million by 2028 to expand at 3.2% CAGR during 2022–2028.
• Based on disease type, the Europe overactive bladder treatment market is bifurcated into idiopathic overactive bladder and neurogenic bladder. The idiopathic overactive bladder segment held 59.2% market share in 2022, amassing US$ 657.75 million. It is projected to garner US$ 794.79 million by 2028 to expand at 3.2% CAGR during 2022–2028.
• Based on country, the Europe overactive bladder treatment market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that the UK captured 27.7% market share in 2022. It was assessed at US$ 307.32 million in 2022 and is likely to hit US$ 369.19 million by 2028, exhibiting a CAGR of 3.1% during the forecast period.

Key players dominating the Europe overactive bladder treatment market are AbbVie Inc; Alembic Pharmaceuticals Limited; Astellas Pharma Inc; Endo Pharmaceuticals Inc.; Hisamitsu Pharmaceutical Co., Inc.; Medtronic Plc; Pfizer Inc; and Teva Pharmaceutical Industries Ltd, among others.

• In Feb 2022, InterStim systems are the standard of care in advanced therapy options, and the most personalized system, to deliver sacral neuromodulation (SNM) therapy.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com